Clinical Trial Update: Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination [Phase 2]

View source ↗

Summary

Phase 2 trial updating safety and immunogenicity of a pneumococcal vaccine in children 12-23 months at first vaccination; results completed and posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Streptococcal

Drugs mentioned

• Pneumococcal Vaccine 2189242A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 2 | Status: COMPLETED | Results posted: 2017-10-06